To do this we analysed the TP53 germline-mutant cohort alongside TP53 somatic-mutant (n = 15) and TP53-wildtype (n = 33) tumor samples, as part of the SickKids Cancer Sequencing (KiCS) childhood precision medicine program27. This evidence concerns the gene TP53 and neoplasm.